Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN45741714
ISRCTN45741714
Completed
Not Applicable

Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivity

ProStrakan Pharmaceuticals (UK)0 sites320 target enrollmentFebruary 6, 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHypogonadal men with decreased insulin sensitivityNutritional, Metabolic, EndocrineTesticular hypofunction

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hypogonadal men with decreased insulin sensitivity
Sponsor
ProStrakan Pharmaceuticals (UK)
Enrollment
320
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 6, 2006
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
ProStrakan Pharmaceuticals (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\.Hypogonadal males
  • •2\.Decreased insulin sensitivity

Exclusion Criteria

  • •1\.Use of testosterone replacement therapy in the last six months
  • •2\.History of or current prostate carcinoma

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520
Active, not recruiting
Not Applicable
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus
EUCTR2005-002607-17-ITSTRAKAN PHARMACEUTICALS LIMITED320
Active, not recruiting
Phase 1
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-GBProstrakan Pharmaceuticals Ltd520
Active, not recruiting
Not Applicable
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2
EUCTR2005-002607-17-BEProStrakan Ltd520
Active, not recruiting
Phase 1
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes MellitusEfecto de la terapia sustitutiva de testosterona transdérmica en hombres hipogonadales o con síndrome metabólico o con diabetes mellitus tipo 2 - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-ESStrakan Pharmaceuticals Ltd530